What is the unique feature of Oritavancin (Orbactiv) regarding its administration?

Oritavancin (Orbactiv) is notable for being the only approved single-dose treatment for complex skin and skin structure infections (SSSIs). This unique feature is significant because it simplifies the treatment regimen for patients and healthcare providers alike. Traditionally, antibiotics for SSSIs often require multiple doses over several days, which can complicate patient adherence and increase the likelihood of incomplete treatment.

By allowing for a single administration, Oritavancin not only improves convenience for the patient but also helps ensure that the full dosage is received at one time, potentially enhancing efficacy. This aspect of Oritavancin makes it particularly valuable in outpatient settings where ease of administration can improve overall treatment outcomes.

The other aspects of Oritavancin do not accurately reflect its characteristics; for instance, while it is indeed an intravenous medication, it is not designated for oral use and does not need to be injected intramuscularly. Additionally, the requirement for multiple doses does not apply, reinforcing that its single-dose capability stands out in its profile.